Literature DB >> 9212576

Psychosis during disulfiram therapy for alcoholism.

K K Murthy1.   

Abstract

Fifty-two patients (51 males, one female) of alcohol dependence/abuse diagnosed according to DSM 111 R1 were registered for disulfiram treatment and were admitted for a 4-week period. No alcohol challenge test was given during their hospital stay. Disulfiram tablets were administered 250 mg twice daily after food. After one week's hospital stay with disulfiram therapy they were sent home to be followed up initially after 15 days and later on once a month. Six male patients developed psychotic symptoms. All of them had shown a mood disorder but no thought disorder was observed. Psychotic symptoms remitted completely after withdrawing disulfiram and then a short course of antipsychotic therapy was given, except in one patient who had to be given lithium for remission of symptoms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9212576

Source DB:  PubMed          Journal:  J Indian Med Assoc        ISSN: 0019-5847


  6 in total

Review 1.  Safety issues concerning the use of disulfiram in treating alcohol dependence.

Authors:  J Chick
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

2.  CURRENT STATUS OF DISULFIRAM THERAPY.

Authors:  P K Chakraborty; H Singh; K J Divinakumar
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 3.  mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse.

Authors:  Meriem Gaval-Cruz; David Weinshenker
Journal:  Mol Interv       Date:  2009-08

4.  Psychosis and enuresis during disulfiram therapy.

Authors:  P A Sherif; K Krishna Murthy
Journal:  Indian J Psychiatry       Date:  2006-01       Impact factor: 1.759

5.  Psychiatric side effects of medications prescribed in internal medicine.

Authors:  Rodrigo Casagrande Tango
Journal:  Dialogues Clin Neurosci       Date:  2003-06       Impact factor: 5.986

6.  Disulfiram Induced Psychosis.

Authors:  Satyakam Mohapatra; Nihar Ranjan Rath
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-02-28       Impact factor: 2.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.